logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.

    Article - En anglais

    Background 

    Our aim was to determine the cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care organization settings.

    Method 

    We employed cost-utility analysis based on a clinical decision analysis model derived from published medical literature and physician judgment.

    The model, which represents ideal primary care practice, compares treatment with nefazodone to treatment with either imipramine or fluoxetine or to a step approach involving initial treatment with imipramine followed by nefazodone for treatment failures.

    The outcome measures were lifetime medical costs, quality-adjusted life years (QALYs), and costs per QALY gained.

    Results 

    The base case analysis found that nefazodone treatment had $16,669 in medical costs, compared with $15,348 for imipramine, $16,061 for the imipramine step approach, and $16,998 for fluoxetine.

    QALYs were greatest for nefazodone (14.64), compared with 14.32 for imipramine, 14.40 for the step approach, and 14.58 for fluoxetine.

    The cost-effectiveness ratio comparing nefazodone with imipramine was $4065 per QALY gained.

    The cost-effectiveness ratio comparing nefazodone with the step approach was $2555 per QALY gained.

    There were only minor differences in costs and outcomes between nefazodone and fluoxetine, with nefazodone resulting in $329 fewer costs and 0.06 more QALYs. (...)

    Mots-clés Pascal : Etat dépressif, Trouble humeur, Chimiothérapie, Antidépresseur, Psychotrope, Etude comparative, Composé tricyclique, Inhibiteur recapture, Sérotonine, Analyse coût, Soin intégré, Qualité vie, Economie santé, Néfazodone, Imipramine, Fluoxétine, Homme

    Mots-clés Pascal anglais : Depression, Mood disorder, Chemotherapy, Antidepressant agent, Psychotropic, Comparative study, Tricyclic compound, Reuptake inhibitor, Serotonin, Cost analysis, Managed care, Quality of life, Health economy, Nefazodone, Imipramine, Fluoxetine, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0250251

    Code Inist : 002B02B02. Création : 11/06/1997.